Back to Journals » Drug Design, Development and Therapy » Volume 15

Therapeutic Effects of Modified Gengnianchun Formula on Stress-Induced Diminished Ovarian Reserve Based on Experimental Approaches and Network Pharmacology [Erratum]

Authors Gao L, Zhang Y, Xu H, Zhao F, Wang W

Received 15 January 2021

Accepted for publication 15 January 2021

Published 27 January 2021 Volume 2021:15 Pages 349—350

DOI https://doi.org/10.2147/DDDT.S302182



Gao L, Zhang Y, Xu H, Zhao F, Wang W. Drug Des Devel Ther. 2020;14:4975–4992


The authors have advised that there was an error in the author list on page 4975 which was introduced by the Editorial staff during the publication process.


The correct author list and affiliations are as follows:
Lingyun Gao1,2,*
Yang Zhang1,2,*
Huangfang Xu2
Fangui Zhao2,3
Wenjun Wang1,2

1Department of Integrated Traditional Chinese Medicine and Western Medicine, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People’s Republic of China; 2Shanghai Key Laboratory
of Female Reproductive Endocrine Related Diseases, Shanghai 200011, People’s Republic of China; 3Department of Ultrasound Diagnosis, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People’s Republic of China


*These authors contributed equally to this work

There was also an error on page 4990. Acknowledgment section, the acknowledgment “Lingyun Gao and Yang Zhang are joint first authors” was not included by Editorial staff.

Read the original article

Creative Commons License © 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.